February 19, 2021

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

February 12, 2021

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference

January 7, 2021

TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

December 15, 2020

TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial

November 12, 2020

TFF Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

November 5, 2020

TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results

November 5, 2020

TFF Pharmaceuticals and Felix Biotechnology Sign Letter of Intent for a Collaboration, Development and License Agreement

November 2, 2020

TFF Pharmaceuticals, Inc. and Augmenta Bioworks, Inc. Enter Into a Worldwide Joint Development Agreement for COVID-19 Monoclonal Antibody Therapies

October 28, 2020

TFF Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020

October 27, 2020

TFF Pharmaceuticals Announces Positive Preclinical Results with University of Georgia Universal Influenza Vaccines